Daclizumab (Zenapax)

An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS.

Also Known As:

Networked: 294 relevant articles (49 outcomes, 61 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Bielekova, Bibiana: 16 articles (01/2019 - 06/2004)
2.	Waldmann, Thomas A: 13 articles (05/2020 - 11/2003)
3.	Giovannoni, Gavin: 8 articles (10/2020 - 06/2013)
4.	Martin, Roland: 7 articles (12/2014 - 06/2004)
5.	Gold, Ralf: 6 articles (10/2020 - 06/2013)
6.	Elkins, Jacob: 6 articles (01/2018 - 04/2010)
7.	Rose, John W: 6 articles (10/2017 - 12/2004)
8.	Ohayon, Joan: 6 articles (03/2016 - 06/2004)
9.	Nussenblatt, Robert B: 6 articles (11/2009 - 11/2003)
10.	Foster, C Stephen: 6 articles (05/2009 - 10/2004)

Related Diseases

1.	Relapsing-Remitting Multiple Sclerosis 04/18/2012 - "The anti-CD25 treatment of daclizumab appears to be effective in patients with relapsing remitting multiple sclerosis (RRMS) as regards clinical and MRI outcomes. " 06/16/2010 - "The anti-CD25 treatment of daclizumab appears to be effective in patients with relapsing remitting multiple sclerosis (RRMS) as regards clinical and MRI outcomes. " 10/01/2020 - "Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study." 01/01/2018 - "Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study." 10/01/2017 - "Results of Phase II and III clinical trials showed efficacy of daclizumab in relapsing-remitting multiple sclerosis, with reduction of annualized relapse rate by 50-54% versus placebo and 45% versus intramuscular IFN-β-1a. "
2.	Multiple Sclerosis 03/11/2019 - "Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis." 01/01/2021 - "EXTEND (NCT01797965), an open-label extension study, evaluated the safety and efficacy of daclizumab beta in participants with relapsing multiple sclerosis (MS) who had completed the randomized DECIDE study. " 01/01/2021 - "Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination." 10/01/2017 - "In subsequent early testing, followed by larger-scale phase II and phase III trials, both intravenous and subcutaneous daclizumab have demonstrated clinical efficacy in the treatment of multiple sclerosis. " 10/01/2020 - "SELECTED, an open-label extension study, evaluated daclizumab beta treatment for up to 6 years in participants with relapsing multiple sclerosis who completed the randomized SELECT/SELECTION studies. "
3.	Inflammation (Inflammations) 04/01/2001 - "When Daclizumab treatment was started well after immunization but before the expected onset of CIA a significant reduction of joint-inflammation and joint-erosion was observed. " 05/01/2009 - "Daclizumab is effective in controlling inflammation in patients with stubborn non-infectious ocular inflammation. " 10/01/2007 - "Four of 10 eyes (40%) in the daclizumab group demonstrated an improvement in vision with eight of 10 eyes (80%) demonstrating an improvement in inflammation. " 12/01/2014 - "Clinical efficacy and safety of daclizumab in MS has so far been tested in several smaller phase II trials and recently two large phase II trials (combined 912 patients), and has shown efficacy regarding reduction of clinical disease activity as well as CNS inflammation. " 04/01/2001 - "The results of this study indicate that Daclizumab has clinical potential for the treatment of RA during periods of active inflammation and suppression of the destruction of the joint tissues."
4.	Uveitis 12/01/2004 - "Daclizumab is effective and safe for long-term use in the treatment of uveitis which cannot be kept under control by other treatments. " 09/01/2008 - "Following promising observations in uveitis, daclizumab has since been tested in a number of small clinical trials in MS based on the rationale that blocking CD25 would prevent the expansion of autoreactive T-lymphocytes. " 11/01/2003 - "In the long-term study, seven of ten enrolled patients were tapered from their original immunosuppressive medications and maintained exclusively on repeated daclizumab infusions for control of their uveitis for over 4 years. " 12/01/2011 - "We further show that the majority of the memory Th17 cells in human blood are Th17-DP and are targets of daclizumab, an IL-2R antibody used in treating recalcitrant uveitis. " 09/01/2008 - "High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis."
5.	Infections 05/01/2004 - "The adverse-event profiles were comparable among the three groups, except for a higher incidence of infection and readmissions in group III. Daclizumab was safe and effective in reducing the incidence of acute rejection when compared to no induction. " 03/01/2001 - "In patients with impaired renal function before LT, daclizumab-based initial immunosuppression can be used safely to reduce the risk for infection and need for dialysis post-LT, with improved long-term graft and patient survival." 01/01/2001 - "Clinical experience from trials to date indicate that daclizumab has a tolerability profile similar to placebo with no significant effect on the incidence of infection. " 09/01/2012 - "Daclizumab was well tolerated, but infections were common. " 07/30/2009 - "The incidence of cytomegalovirus (CMV) disease generally did not differ between rATG and eATG induction, and there was no significant difference between rATG and daclizumab induction with regard to the incidence of CMV infections or the proportion of patients who received treatment for a CMV episode or infection. "

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	Steroids
3.	Interleukin-2 Receptors (IL 2 Receptor)
4.	Alemtuzumab (Campath)
5.	Rituximab (Mabthera)
6.	Interferon beta-1a
7.	Daclizumab (Zenapax)
8.	Cytokines
9.	Etanercept (Enbrel)
10.	Immunosuppressive Agents (Immunosuppressants)

Related Therapies and Procedures

1.	Therapeutics
2.	Subcutaneous Injections
3.	Kidney Transplantation
4.	Aftercare (After-Treatment)
5.	Injections